

**Change in Representative Director, New Executive Team and Management Structure**

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director, President & CEO: Akihiro Tsujimura; hereinafter, “MTPC”) announced that at the General Meeting of Shareholders and the Board of Directors, MTPC resolved the following change of the Representative Director, the new executive team and management structure.

■ Change in Directors of the Board and Executive Team (Effective as of September 1, 2025)

• Newly appointed

New	Name
Representative Director of the Board, Chief Executive Officer,	Akihisa Harada <sup>*1, *2</sup>
Chairman, Director of the Board	Costa Saroukos <sup>*1</sup>
Chief Business Officer	Sean Ryan <sup>*1</sup>
Chief Financial Officer, Head of Finance Div.	Amit Singh <sup>*1</sup>
Chief Information Officer	Keitarou Shigemasa <sup>*1</sup>

<sup>\*1</sup> Scheduled to join on September 1, 2025

<sup>\*2</sup> The advisory contract with Pfizer Japan Inc. is scheduled to end at the end of August 2025

• Biography of the New Representative Director

Name	Akihisa Harada	
Date of birth	August 4, 1959	
Education	Graduate School of Medicine, Kanazawa University	
Professional Experience	August 1999 September 2008  August 2016  December 2017  September 1, 2025	Joined Pfizer Japan Inc. Development Japan Head of Pfizer Japan Inc.  President, Inflammatory & Immunology Division of Pfizer Japan Inc. President & Representative Director of Pfizer Japan Inc. <sup>*2</sup> To be appointed Representative Director of the Company

• Change of Job Responsibilities

New	Name	Current
President, Representative Director of the Board, Chief Operating Officer	Akihiro Tsujimura	Representative Director of the Board, President & CEO, Head of Finance Div.


Chief Transformation Officer & General Counsel, Head of Business Development Div.	Kazumasa Nagayama	Executive Officer Corporate Executive Vice President, Head of Business Development Div.
---	-------------------	--

■ Directors of the Board and Executive Team (Effective as of September 1, 2025)

New	Name
Representative Director of the Board, Chief Executive Officer	Akihisa Harada
President, Representative Director of the Board, Chief Operating Officer	Akihiro Tsujimura
Chairman, Director of the Board	Costa Saroukos
Director of the Board	Ryousuke Tanabe
Director of the Board	Yuji Sugimoto
Director of the Board	Masashi Suekane
Director of the Board	Hiroki Inada
Director of the Board	William Cozean
Director of the Board	Nicholas Gattas
Corporate Auditor	Satomi Takada
Corporate Auditor	Shintaro Kohmoto
Chief Transformation Officer & General Counsel, Head of Business Development Div.	Kazumasa Nagayama
Chief Business Officer	Sean Ryan
Chief Financial Officer, Head of Finance Div.	Amit Singh
Chief Information Officer	Keitarou Shigemasa
Chief Medical Officer, Head of Global R&D, and Global Development & Medical Affairs Div.	Bijan Nejadnik
Executive Officer, Head of Corporate Strategy Div.	Tetsurou Iwata
Executive Officer, Head of Legal & Compliance Div.	Michihisa Yatou
Executive Officer, Head of HR & General Affairs Div.	Tomoaki Tokuno
Executive Officer, Head of Research Div.	Naoya Masutomi
Executive Officer, Head of Development & Medical Affairs Div.	Yousuke Kimura
Executive Officer, Head of Product Supply Div.	Kenji Taguchi
Executive Officer, Head of Quality & Vigilance Div.	Masanobu Kono

Executive Officer, Head of Japan Pharmaceutical Business Div.	Yasutaka Kuragaki
Executive Officer, Head of North America Business Div.	Yasutoshi Kawakami
Executive Officer, Head of Asia and Europe Business Div.	Toshifumi Tada

■ Management Structure Chart (Effective as of September 1, 2025)



**Contact:**  
Mitsubishi Tanabe Pharma Corporation  
CEO Office PR Group  
+81-6-6205-5119